The pleural effusion that was initially drained recurred after two weeks but subsequently resolved on follow‑up imaging as part of the patient’s response to chemotherapy. Repeat LDH measurement was ...
After a median follow-up of 13.3 months (95% CI, 9.04-18.69), the median duration of response was 18.1 months, progression ...
A former Victorian cell block that was converted into a modern family home is on sale for $1 million. The Guard House in ...
Topline data of investigator-initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response ...
Many of us would probably like to forget sitting through math classes in school. But let’s briefly travel back, just for a ...
Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...
Background Ocular chronic graft versus host disease (oGVHD) seriously affects ocular surface, which often results in corneal ...
At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...
In early January, the U.S. Department of Health and Human Services removed the recommendation for universal vaccination against bacterial meningitis. The federal agency instead has moved this vaccine ...
BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial ...
At 125 mg palbociclib, two DLTs occurred (grade 3 anemia and grade 3 hypoxia), with no treatment-related deaths; one cerebral hemorrhage death was reported. The LITESPARK-024 trial showed a manageable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results